A comparator trial of BPX-501 in malignant and nonmalignant pediatric patients receiving a matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT).
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2017
At a glance
- Drugs Rivogenlecleucel (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 13 Mar 2017 According to a Bellicum Pharmaceuticals media release, the company expects full enrolled later this year.
- 14 Dec 2016 New trial record
- 05 Dec 2016 According to a Bellicum Pharmaceuticals media release, this trial will include up to 40 prospective patients.